Data from the seventh national census shows that the number of elderly people in China is growing rapidly, and increasing the birth rate is an important measure to cope with the aging of society
Academy of Sciences China Kexue Yuan Stem Cell Institute and the implementation of innovative regenerative medicine dean Songhu Battle of Resistance Yang said that drug development is a human disease fight an effective means of drug development must first understand the therapeutic targets for diseases of major basic research may make forward-looking to find drug targets Sex leads the work
Academy president struggles Academy of Sciences According to reports, in 2017 China Ke Xueyuan stem cells and regeneration of the Academy of Medical Innovation Ferring Pharmaceutical jointly established FIRM, aims to integrate China's leading reproductive biology research strength and characteristics of the platform, is committed to applying the conversion reproductive biology basic research and to promote scientific research , To provide solutions for the prevention, diagnosis, treatment and rehabilitation of related diseases in the field of reproductive health.
Academy of Sciences China Ke Xueyuan Stem Cells and Regenerative Medicine Institute for Innovation reproductive pathology research team leader Wang Yanling researchers report entitled "placental dysfunction and pregnancy-related diseases - for example to pre-eclampsia," the keynote speech
Academy of Sciences Researcher Wang Yanling said that multiple pregnancy diseases such as recurrent miscarriage, preeclampsia, fetal development delay, gestational diabetes, and premature birth threaten the health of mothers and fetuses, resulting in "no birth or poor birth".
Researcher Wang Yanling said that based on the close relationship between pregnancy disease and placental development and dysfunction, the project team explored the mechanism of the imbalance of placental estrogen synthesis causing preeclampsia and other pregnancy diseases, as well as the reasons for the imbalance of androgen synthesis in the placenta of preeclampsia.
Ferring Pharmaceuticals Global Chief Scientific Officer and Medical Officer Mirjam Mol-Arts congratulated FIRM on the achievements of FIRM in the past three years through video and said that the establishment of FIRM is based on our long-term commitment to China and the common basic scientific research of both parties.
Henk Jan Out, Chief Scientific Officer of Ferring Medical Asia Pacific, said that FIRM has established the "Ferring-Stem Cell Innovation Institute Reproductive Health Fund" to support basic and translational research in the field of reproductive biology in China
Academy of Sciences
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
